Loading, Please Wait...

CST: 17/11/2019 22:34:22   

Passage Bio to Present at Barclays Gene Editing & Gene Therapy Summit

11 Days ago

PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that Jill Quigley, chief operating officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Wednesday, November 13th, 2019 at 9:30 a.m. ET in New York, NY.

About Passage Bio
Passage Bio is a privately-held fully integrated genetic medicines company with a mission to develop a portfolio of life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP), as well as the Orphan Disease Center at Penn. The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of six product candidates, with the option to license six more, with lead programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe disease. Since inception, Passage Bio has raised $225.5 million with investments from OrbiMed, Versant Ventures, Frazier Healthcare Partners, Access Biotechnology, Lily Asia Ventures, New Leaf Venture Partners, Vivo Capital, and Boxer Capital of Tavistock Group, among others.

For further information, please contact:

Investors:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

Media:
Emily Maxwell
HDMZ
312-506-5220
emily.maxwell@hdmz.com

Is your business listed correctly on America’s largest city directory network of 1,000 portals?